Oldal 1 tól től 19 eredmények
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 15, 2018, is named 2017-12-00152PA_SL.txt and is 792 bytes in size.
FIELD OF THE
TECHNICAL FIELD OF THE INVENTION
The present invention deals with compositions for ano-rectal inflammatory processes, hemorrhoidal syndromes, pruritus ani and ano-rectal wounds comprising a complex of synergistic antioxidants, including enzymatic co-factors, thiol and selenium compounds, zinc salts
The present invention relates to particular proteins which are glutathione-S-transferases originating from various schistosome parasites, for the use thereof in the treatment of autoimmune inflammatory diseases such as Crohn's disease or multiple sclerosis. The present invention also relates to the
The present invention relates to the use of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS).
It also relates to a composition for implementing this treatment.
The role of selenium, as an oligo-element involved in many reactions in the organism, is widely
The present invention relates to the use of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS).
It also relates to a composition for implementing this treatment.
The role of selenium, as an oligo-element involved in many reactions in the organism, is widely
BACKGROUND OF THE INVENTION
The neutrophil plays a critical role in the pathogenesis of the Adult Respiratory Distress Syndrome (ARDS), as strategies aimed at preventing neutrophil sequestration in the lung, such as neutrophil depletion or administration of antibody directed against adhesion
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the clinical treatment of chronic inflammatory disorders. For purposes of this invention, the category of chronic inflammatory disorders includes chronic gingivitis, chronic periodontitis, chronic autoimmune gastritis,
AIMS OF THE INVENTION
Accordingly, it is a general object of this invention to treat chronic inflammatory diseases by use of systemically administered compositions consisting of (a) a required primary agent which is an orally consumed carbonyl trapping substance selected from the closed group
The present invention relates to the use of Phyllanthus for preventing or treating connective tissue proliferations, for maintaining the level of reduced glutathione, for inhibiting the lipopolysaccharide (LPS)-induced nitric oxide synthase (NOS) and for inhibiting the expression of the
TECHNICAL FIELD OF THE INVENTION
The present invention deals with the combinations of several synergistic antioxidants, including enzymatic co-factors with analgesics such as capsaicin or the local caine anesthetics and anti-inflammatory agents in appropriate delivery vehicles employed in topical
FIELD
The present invention provides compounds having neuroprotective, neurotrophic, anti-inflammatory and/or anti-oxidant properties. The compounds are useful for promoting, enhancing and/or increasing the protection, growth and/or regeneration of neurons. The compounds also find use to increase,
FIELD OF THE INVENTION
The subject of the present invention is new immortalized human corneal epithelial cell lines as well as their use in processes for the identification of agents which are mutagenic, toxic or beneficial to the metabolism of the corneal cells.
BACKGROUND ART
For many years,
BACKGROUND
1. Field of Invention
This invention relates to therapeutic compounds that improve the outcome of preterm deliveries. More specifically, this invention relates to the usage of compounds that are free radical scavengers or that promote the production of free radical scavengers to prevent
FIELD OF THE INVENTION
The invention relates to benzylidene derivatives, and more particularly to benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and derivatives thereof. The invention also relates to the biological activities of the aforementioned compounds in vivo
TECHNICAL FIELD
The invention relates to C-nitroso compounds which are therapeutically active at low concentrations as NO donors.
BACK GROUND OF THE INVENTION
NO donors are known to be useful for therapeutic utility, e.g., to prevent restenosis following angioplasty (Groves, P., et al.,